JAK-IN-23 是一种具有口服活性的 JAK/STAT 和 NF-κB 双重抑制剂,对 JAK1/2/3 的 IC50 值分别为 8.9 nM、15 nM 和 46.2 nM,对干扰素刺激基因 (ISG) 和 NF-κB 通路具有强抑制活性,IC50 值分别为 3.3 nM 和 150.7 nM,具有强抗炎作用并可减少各种促炎因子的释放,可用于炎症性肠病 (IBD) 的研究。
产品编号: MS-A94888 纯度: 98.88% CAS No.: 3031837-35-8 分子式: C23H22Cl2N4O 分子量: 441.35
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

JAK-IN-23 是一种具有口服活性的 JAK/STAT 和 NF-κB 双重抑制剂,对 JAK1/2/3 的 IC50 值分别为 8.9 nM、15 nM 和 46.2 nM,对干扰素刺激基因 (ISG) 和 NF-κB 通路具有强抑制活性,IC50 值分别为 3.3 nM 和 150.7 nM,具有强抗炎作用并可减少各种促炎因子的释放,可用于炎症性肠病 (IBD) 的研究。

生物实验数据

生物活性 JAK-IN-23 is an orally active dual inhibitor of JAK/STAT and NF-κB that inhibits JAK1/2/3 with IC50 values of 8.9 nM, 15 nM, and 46.2 nM, respectively, exhibits potent inhibitory activity against interferon-stimulated genes (ISG) and the NF-κB pathway with IC50 values of 3.3 nM and 150.7 nM, respectively, exerts strong anti-inflammatory effects by reducing the release of various pro-inflammatory factors, and can be used for research on inflammatory bowel disease (IBD).
IC50 & Target

JAK1

8.9 nM (IC50)

JAK2

15 nM (IC50)

JAK3

46.2 nM (IC50)

NF-κB

150.7 nM (IC50)

ISG

3.3 nM (IC50)

体外研究
(In Vitro)

JAK-IN-23 inhibits JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively.
JAK-IN-23 shows potent inhibitory activities against ISG and NF-KB with IC50 values of 3.3 nM and 150.7 nM, respectively.
WB--- JAK-IN-23 (0.33μM, 1μM, 3μM; 24 h) can simultaneously block JAK-STAT1/3 and NF-κB proinflammatory signaling pathways in THP1-dual cells.
JAK-IN-23 (0.003-3 μM; 24 h) decreases the release of various proinflammatory factors, including IL-6, IL-8, IL-1β in THP1-dual cells stimulated by LPS.
JAK-IN-23 (0.11-3 μM; 24 h) decreases the release of various proinflammatory factors, including TNF-α, IL-12, IL-10 and IFNγ in LPS-induced peripheral blood mononuclear cells (PBMCs).
JAK-IN-23 (1 μM) inhibits the expression of a variety of inflammation-related genes induced by LPS, including IL-1B, TNF, IL12B, and IL-23A and has inhibitory effects on the expression of genes involved in the unfolded protein response that was induced by LPS (1 μg/mL).

Western Blot Analysis

Cell Line: THP1-Dual Cells
Concentration: 0.33μM, 1μM, 3μM
Incubation Time: 24 h
Result: Inhibited p-STAT1/3 in a dose-dependent manner that was induced by IL-6, as well as inhibited pNF-κB p65 in a dose-dependent manner, but not on MYD88 and p-IKK α/β that was induced by LPS.
体内研究
(In Vivo)

JAK-IN-23 (1-5 mg/kg, oral) produces a strong anti-inflammatory activity in both dextran sulfate sodium (DSS) - and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced acute enteritis models and restores the structural composition of gut microbiota.

Animal Model: DSS-Induced Acute Colitis Mice Model
Dosage: 1 mg/kg, 3 mg/kg
Administration: oral
Result: Significantly decreased the DAI scores (1 and 3 mg/kg).
Recovered the length of the colon (3 mg/kg).
Significantly reduced the histopathology of ulcerative colitis (1 and 3 mg/kg).
Animal Model: The BALB/c mouse inflammatory bowel disease (IBD) model
Dosage: 1 mg/kg, 5 mg/kg
Administration: oral
Result: Significantly improved the survival probability, had low DAI scores and effectively relieved symptoms of colitis in the TNBS-induced IBD mice model (5 mg/kg).
Did not improve the survival probability and decreases the DAI score (100 mg/kg).
性状 固体
颜色 Light brown to gray

化学信息

分子量 441.35
分子式 C23H22Cl2N4O
CAS No. 3031837-35-8

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 5 mg/mL (11.33 mM; 超声助溶 (<80°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2658 mL11.3289 mL22.6578 mL56.6444 mL
5 mM0.4532 mL2.2658 mL4.5316 mL11.3289 mL
10 mM0.2266 mL1.1329 mL2.2658 mL5.6644 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础